Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol
Public ClinicalTrials.gov record NCT01265264. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral Ulodesine Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine whether ulodesine and allopurinol combined for 12 weeks are effective in treating gout in patients who are not adequately responding to allopurinol alone.
Study identification
- NCT ID
- NCT01265264
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 279 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 69 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2010
- Primary completion
- Jun 30, 2012
- Completion
- Jan 31, 2013
- Last update posted
- Nov 19, 2013
2010 – 2013
United States locations
- U.S. sites
- 54
- U.S. states
- 29
- U.S. cities
- 54
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | — | — |
| Not listed | Mobile | Alabama | — | — |
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Scottsdale | Arizona | — | — |
| Not listed | Tucson | Arizona | — | — |
| Not listed | Malvern | Arkansas | — | — |
| Not listed | Anaheim | California | — | — |
| Not listed | Burbank | California | — | — |
| Not listed | Irvine | California | — | — |
| Not listed | La Mesa | California | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | Oceanside | California | — | — |
| Not listed | Palm Springs | California | — | — |
| Not listed | Paramount | California | — | — |
| Not listed | Sacramento | California | — | — |
| Not listed | San Jose | California | — | — |
| Not listed | Walnut Creek | California | — | — |
| Not listed | West Covina | California | — | — |
| Not listed | DeLand | Florida | — | — |
| Not listed | Edgewater | Florida | — | — |
| Not listed | Gainesville | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Oldsmar | Florida | — | — |
| Not listed | Sanford | Florida | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Honolulu | Hawaii | — | — |
| Not listed | Meridian | Idaho | — | — |
| Not listed | Gurnee | Illinois | — | — |
| Not listed | Brownsburg | Indiana | — | — |
| Not listed | Newton | Kansas | — | — |
| Not listed | Lexington | Kentucky | — | — |
| Not listed | Baltimore | Maryland | — | — |
| Not listed | Springfield | Massachusetts | — | — |
| Not listed | Lansing | Michigan | — | — |
| Not listed | Olive Branch | Mississippi | — | — |
| Not listed | Omaha | Nebraska | — | — |
| Not listed | Albuquerque | New Mexico | — | — |
| Not listed | Charlotte | North Carolina | — | — |
| Not listed | Greensboro | North Carolina | — | — |
| Not listed | Raleigh | North Carolina | — | — |
| Not listed | Salisbury | North Carolina | — | — |
| Not listed | Winston-Salem | North Carolina | — | — |
| Not listed | Cincinnati | Ohio | — | — |
| Not listed | Cleveland | Ohio | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Duncansville | Pennsylvania | — | — |
| Not listed | Greer | South Carolina | — | — |
| Not listed | Rapid City | South Dakota | — | — |
| Not listed | Bristol | Tennessee | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Salt Lake City | Utah | — | — |
| Not listed | Richmond | Virginia | — | — |
| Not listed | Tacoma | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01265264, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 19, 2013 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01265264 live on ClinicalTrials.gov.